公开(公告)号：US12227569B2

公开(公告)日：2025-02-18

申请号：US17376314

申请日：2021-07-15

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  C07K16/30

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US12195555B2

公开(公告)日：2025-01-14

申请号：US18469947

申请日：2023-09-19

Applicant: SANOFI ,  INNATE PHARMA

Inventor： Nicolas Gourdin ,  Laurent Gauthier ,  Alexandre Tang ,  Marielle Chiron ,  Angela Virone-Oddos ,  Alessandro Masiero ,  Jochen Beninga ,  Ingo Focken ,  Sambasiva Rao ,  Yanfeng Zhou ,  Leila Sevigny

IPC: C07K16/46 ,  A61P35/00 ,  C12N15/63

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

公开(公告)号：US11267897B2

公开(公告)日：2022-03-08

申请号：US16173114

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: A61P43/00 ,  C07K16/28 ,  C12N15/62

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20200024357A1

公开(公告)日：2020-01-23

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US09944712B2

公开(公告)日：2018-04-17

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

公开(公告)号：US20130189287A1

公开(公告)日：2013-07-25

申请号：US13725382

申请日：2012-12-21

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Eliane Fischer ,  Laurent Gauthier ,  Francois Romagné ,  Roger Schibli

IPC: C07K19/00 ,  C12P21/00 ,  C12N9/10 ,  C07C323/60 ,  C07C323/12 ,  C07C247/04 ,  C07D225/08 ,  C07C217/08 ,  C07C229/26 ,  C07C233/62 ,  C07D277/06 ,  C07F9/50 ,  C07D257/08 ,  C07C223/02 ,  G01N33/68

CPC classification number: A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions

Abstract translation: 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法

公开(公告)号：US11858990B2

公开(公告)日：2024-01-02

申请号：US16804018

申请日：2020-02-28

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Simon Kollnberger ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel ,  Stéphanie Cornen ,  Stéphanie Zerbib

IPC: A61P35/00 ,  C07K16/28 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2803 ,  G01N33/56966 ,  G01N33/56972 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  G01N2333/70503 ,  G01N2800/24 ,  G01N2800/52 ,  G01N2800/7095

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US11845795B2

公开(公告)日：2023-12-19

申请号：US16677709

申请日：2019-11-08

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20230025732A1

公开(公告)日：2023-01-26

申请号：US17855510

申请日：2022-06-30

Applicant: Innate Pharma ,  Orega Biotech

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11066470B2

公开(公告)日：2021-07-20

申请号：US16398472

申请日：2019-04-30

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K39/00 ,  A61K9/00

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.